title: [Clinical cfficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension].
abstract: The review describes the classification, mechanisms of action, the effects of calcium channel blockers slow and the clinical benefits of dihydropyridine calcium antagonists, the third generation. Presented modern aspects of clinical pharmacology and research results on the efficacy, safety and organoprotective lercanidipine.
authors: M L
authors: ML
authors: Maksimov
authors: A I
authors: AI
authors: Malykhina
mesh_terms: D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000145:classification / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000378:metabolism*; D004095:Dihydropyridines / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism; D054539:Medication Therapy Management; D017063:Outcome Assessment, Health Care; D020011:Protective Agents; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D004095:Dihydropyridines; D020011:Protective Agents; C060343:lercanidipine